NCT01857934 2026-04-16
Therapy for Children With Advanced Stage Neuroblastoma
St. Jude Children's Research Hospital
Phase 2 Completed
Clinical Trials
19 trialsNCT06366347 2026-02-11
ALPINE: Maintenance Letrozole/Abemaciclib
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT06550141 2025-11-14
Emapalumab Prevention of CAR-T Cell Associated Toxicities
Massachusetts General Hospital
Phase 2 Recruiting
NCT05462496 2024-10-15
Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer
Icahn School of Medicine at Mount Sinai
Phase 2 Recruiting
NCT03942224 2024-06-21
DeRIVE
Emory University
Phase 2 Active not recruiting
NCT06115174 2023-11-02
CRC - PTX
Tanta University
Phase 4 Unknown
NCT01873833 2023-10-05
Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer
University of Southern California
Phase 2 Terminated
NCT05073250 2023-05-12
IBI376 Plus Rituximab in Patients With Untreated Indolent Lymphoma.
Chinese PLA General Hospital
Phase 2 Unknown
NCT03112590 2023-04-19
Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Completed
NCT02713373 2022-10-06
Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery
Roswell Park Cancer Institute
Phase 1/2 Completed
NCT04315467 2022-06-16
Intraoperative Imaging of Pulmonary Nodules by SGM-101
Abramson Cancer Center at Penn Medicine
Phase 1 Completed
NCT02855086 2020-03-31
Cetuximab-IRDye 800CW in Detecting Tumors in Patients With Malignant Glioma Undergoing Surgery
Stanford University
Phase 1/2 Terminated
NCT01136395 2019-10-08
Impact of Rituximab (RTx) Induction and Living Donation on Immunoregulation and Virus Control in Renal Transplantation
University of Giessen
Phase 2 Completed
NCT00681993 2019-01-22
PBIC
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase NA Completed
NCT03631836 2018-08-17
MARELLE01
Assistance Publique Hopitaux De Marseille
Phase 1 Unknown
NCT00989586 2017-02-06
Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 1/2 Completed
NCT00052403 2014-01-16
Monoclonal Antibody Therapy in Treating Patients With Advanced Solid Tumors
Barbara Ann Karmanos Cancer Institute
Phase 1 Withdrawn
NCT00142155 2011-06-27
Correlation of FC Gamma RIIIA Receptor Response in Patients With Waldenstrom's Macroglobulinemia
Dana-Farber Cancer Institute
Phase NA Completed
NCT00515892 2007-08-14
NHL
Cambridge Antibody Technology
Phase 1 Unknown